文献速递重症综合管理与镇静镇痛

预防性褪黑素治疗重症监护谵妄(Pro-MEDIC):一项随机对照试验

Prophylactic melatonin for delirium in intensive care (Pro-MEDIC): a randomized controlled trial.
PubMed 文献 · Intensive Care Med · 2022-02-27
一句话结论多中心随机对照试验显示,ICU入院48小时内启动肠内褪黑素4 mg不降低谵妄发生比例,不支持下述常规早期使用。

这项多中心、随机、安慰剂对照、双盲试验在12个澳大利亚ICU纳入847例预计ICU停留>72小时、入院48小时内入组的成人患者,比较肠内褪黑素4 mg(n=419)与安慰剂(n=422)每晚21:00连续14晚或至ICU出院的疗效。主要终点为14天内或ICU出院前无谵妄评估的比例,褪黑素组79.2% vs 安慰剂组80%(p=0.547),无显著差异;ICU住院时间、医院住院时间、90天死亡率及睡眠质量与数量等次要终点亦无显著差异,两组均无严重不良事件报告。结论认为肠内褪黑素未能降低谵妄发生比例,不支持下述常规早期使用。

要点

  • 在12个澳大利亚ICU的847例成人危重患者中,肠内褪黑素4 mg每晚21:00连续14晚或至ICU出院,未降低谵妄发生比例(无谵妄评估比例79.2% vs 80%,p=0.547)。
  • 褪黑素组与安慰剂组ICU住院时间中位数均为5天(p=0.135),医院住院时间中位数14 vs 12天(p=0.816),均无显著差异。
  • 90天死亡率褪黑素组15.5% vs 安慰剂组15.6%(p=0.948),无显著差异;任何时间点死亡率亦无显著差异。
  • 睡眠质量与数量、ICU住院时间、医院住院时间及死亡率等次要终点均无显著差异,两组均无严重不良事件报告。
  • 作者结论认为肠内褪黑素未降低谵妄发生比例,不支持下述常规早期使用褪黑素。

适用人群与场景

  • 年龄≥18岁、需入住ICU且预计ICU停留时间>72小时的成人患者,于ICU入院48小时内入组。
  • 研究在12个澳大利亚ICU进行,招募时间为2016年7月至2019年9月。

诊断标准与关键阈值

  • 谵妄评估采用ICU意识模糊评估法(CAM-ICU)评分,每日评估两次。
  • 主要终点为14天内或ICU出院前无谵妄评估的比例,作为谵妄发生比例的标志。

处置流程与药物剂量

  • 肠内给予外观不可区分的褪黑素液体4 mg(n=419)或安慰剂(n=422),每晚21:00给药,连续14晚或直至ICU出院。

研究设计与关键结果

  • 多中心、随机、安慰剂对照、双盲试验,共随机847例患者,841例纳入数据分析;两组基线特征相似。
  • 主要终点:褪黑素组与安慰剂组每例患者平均无谵妄评估比例分别为79.2% vs 80%,无显著差异(p=0.547)。
  • 次要终点:ICU住院时间中位数5 vs 5天(p=0.135),医院住院时间中位数14 vs 12天(p=0.816),90天死亡率15.5% vs 15.6%(p=0.948),任何时间点死亡率及睡眠质量与数量均无显著差异。
  • 两组均无严重不良事件报告。

证据类型、等级与局限

  • 证据类型:多中心随机安慰剂对照双盲试验(RCT)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者结论认为肠内褪黑素未降低谵妄发生比例,不支持下述常规早期使用褪黑素。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

PURPOSE: Delirium is common in the critically ill, highly distressing to patients and families and associated with increased morbidity and mortality. Results of studies on preventative use of melatonin in various patient groups have produced mixed results. The aim of this study was to determine whether administration of melatonin decreases the prevalence of delirium in critically ill patients.

METHODS: Multicentre, randomized, placebo-controlled, double-blind trial across 12 Australian ICUs recruiting patients from July 2016 to September 2019. Patients of at least 18 years requiring ICU admission with an expected length of stay (LOS) greater than 72 h; enrolled within 48 h of ICU admission. Indistinguishable liquid melatonin (4 mg; n = 419) or placebo (n = 422) was administered enterally at 21:00 h for 14 consecutive nights or until ICU discharge. The primary outcome was the proportion of delirium-free assessments, as a marker of delirium prevalence, within 14 days or before ICU discharge. Delirium was assessed twice daily using the Confusion Assessment Method for ICU (CAM-ICU) score. Secondary outcomes included sleep quality and quantity, hospital and ICU LOS, and hospital and 90-day mortality.

RESULTS: A total of 847 patients were randomized into the study with 841 included in data analysis. Baseline characteristics of the participants were similar. There was no significant difference in the average proportion of delirium-free assessments per patient between the melatonin and placebo groups (79.2 vs 80% respectively, p = 0.547). There was no significant difference in any secondary outcomes including ICU LOS (median: 5 vs 5 days, p = 0.135), hospital LOS (median: 14 vs 12 days, p = 0816), mortality at any time point including at 90 days (15.5 vs 15.6% p = 0.948), nor in the quantity or quality of sleep. There were no serious adverse events reported in either group.

CONCLUSION: Enteral melatonin initiated within 48 h of ICU admission did not reduce the prevalence of delirium compared to placebo. These findings do not support the routine early use of melatonin in the critically ill.

来源:Intensive Care Med,查看原文。版权归原作者所有。

参考来源

  1. Wibrow B, Martinez FE, Myers E, et al. Prophylactic melatonin for delirium in intensive care (Pro-MEDIC): a randomized controlled trial. Intensive Care Med. 2022. PMID: 35220473. doi:10.1007/s00134-022-06638-9

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。